181 related articles for article (PubMed ID: 25486424)
21. New quinolone- and 1,8-naphthyridine-3-carboxamides as selective CB2 receptor agonists with anticancer and immuno-modulatory activity.
Manera C; Malfitano AM; Parkkari T; Lucchesi V; Carpi S; Fogli S; Bertini S; Laezza C; Ligresti A; Saccomanni G; Savinainen JR; Ciaglia E; Pisanti S; Gazzerro P; Di Marzo V; Nieri P; Macchia M; Bifulco M
Eur J Med Chem; 2015 Jun; 97():10-8. PubMed ID: 25935384
[TBL] [Abstract][Full Text] [Related]
22. CB2-selective cannabinoid receptor ligands: synthesis, pharmacological evaluation, and molecular modeling investigation of 1,8-Naphthyridin-2(1H)-one-3-carboxamides.
Lucchesi V; Hurst DP; Shore DM; Bertini S; Ehrmann BM; Allarà M; Lawrence L; Ligresti A; Minutolo F; Saccomanni G; Sharir H; Macchia M; Di Marzo V; Abood ME; Reggio PH; Manera C
J Med Chem; 2014 Nov; 57(21):8777-91. PubMed ID: 25272206
[TBL] [Abstract][Full Text] [Related]
23. Systematic Modification of the Substitution Pattern of the 7-Hydroxy-5-oxopyrazolo[4,3-
Mugnaini C; Kostrzewa M; Casini M; Kumar P; Catallo V; Allarà M; Guastaferro L; Brizzi A; Paolino M; Tafi A; Kapatais C; Giorgi G; Vacondio F; Mor M; Corelli F; Ligresti A
Molecules; 2023 Jun; 28(13):. PubMed ID: 37446625
[TBL] [Abstract][Full Text] [Related]
24. Structure-activity relationships of substituted 1H-indole-2-carboxamides as CB1 receptor allosteric modulators.
Nguyen T; German N; Decker AM; Li JX; Wiley JL; Thomas BF; Kenakin TP; Zhang Y
Bioorg Med Chem; 2015 May; 23(9):2195-2203. PubMed ID: 25797163
[TBL] [Abstract][Full Text] [Related]
25. Decahydroquinoline amides as highly selective CB2 agonists: role of selectivity on in vivo efficacy in a rodent model of analgesia.
Manley PJ; Zartman A; Paone DV; Burgey CS; Henze DA; Della Penna K; Desai R; Leitl MD; Lemaire W; White RB; Yeh S; Urban MO; Kane SA; Hartman GD; Bilodeau MT; Trotter BW
Bioorg Med Chem Lett; 2011 Apr; 21(8):2359-64. PubMed ID: 21420857
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and SAR of novel imidazoles as potent and selective cannabinoid CB2 receptor antagonists with high binding efficiencies.
Lange JH; van der Neut MA; Wals HC; Kuil GD; Borst AJ; Mulder A; den Hartog AP; Zilaout H; Goutier W; van Stuivenberg HH; van Vliet BJ
Bioorg Med Chem Lett; 2010 Feb; 20(3):1084-9. PubMed ID: 20031412
[TBL] [Abstract][Full Text] [Related]
27. Investigations on the 4-quinolone-3-carboxylic acid motif. 6. Synthesis and pharmacological evaluation of 7-substituted quinolone-3-carboxamide derivatives as high affinity ligands for cannabinoid receptors.
Pasquini S; De Rosa M; Ligresti A; Mugnaini C; Brizzi A; Caradonna NP; Cascio MG; Bolognini D; Pertwee RG; Di Marzo V; Corelli F
Eur J Med Chem; 2012 Dec; 58():30-43. PubMed ID: 23085772
[TBL] [Abstract][Full Text] [Related]
28. Design, syntheses, structure-activity relationships and docking studies of coumarin derivatives as novel selective ligands for the CB2 receptor.
Han S; Zhang FF; Qian HY; Chen LL; Pu JB; Xie X; Chen JZ
Eur J Med Chem; 2015 Mar; 93():16-32. PubMed ID: 25644673
[TBL] [Abstract][Full Text] [Related]
29. 6-Methoxy-N-alkyl isatin acylhydrazone derivatives as a novel series of potent selective cannabinoid receptor 2 inverse agonists: design, synthesis, and binding mode prediction.
Diaz P; Phatak SS; Xu J; Astruc-Diaz F; Cavasotto CN; Naguib M
J Med Chem; 2009 Jan; 52(2):433-44. PubMed ID: 19115816
[TBL] [Abstract][Full Text] [Related]
30. N-Alkylidenearylcarboxamides as new potent and selective CB(2) cannabinoid receptor agonists with good oral bioavailability.
Ohta H; Ishizaka T; Tatsuzuki M; Yoshinaga M; Iida I; Tomishima Y; Toda Y; Saito S
Bioorg Med Chem Lett; 2007 Nov; 17(22):6299-304. PubMed ID: 17884496
[TBL] [Abstract][Full Text] [Related]
31. Developing pyridazine-3-carboxamides to be CB2 agonists: The design, synthesis, structure-activity relationships and docking studies.
Qian HY; Wang ZL; Xie XY; Pan YL; Li GJ; Xie X; Chen JZ
Eur J Med Chem; 2017 Sep; 137():598-611. PubMed ID: 28651225
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and biological evaluation of new N-alkyl 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides as cannabinoid receptor ligands.
Silvestri R; Ligresti A; La Regina G; Piscitelli F; Gatti V; Lavecchia A; Brizzi A; Pasquini S; Allarà M; Fantini N; Carai MA; Bigogno C; Rozio MG; Sinisi R; Novellino E; Colombo G; Di Marzo V; Dondio G; Corelli F
Eur J Med Chem; 2010 Dec; 45(12):5878-86. PubMed ID: 20943290
[TBL] [Abstract][Full Text] [Related]
33. Investigations on the 4-Quinolone-3-carboxylic Acid Motif. 7. Synthesis and Pharmacological Evaluation of 4-Quinolone-3-carboxamides and 4-Hydroxy-2-quinolone-3-carboxamides as High Affinity Cannabinoid Receptor 2 (CB2R) Ligands with Improved Aqueous Solubility.
Mugnaini C; Brizzi A; Ligresti A; Allarà M; Lamponi S; Vacondio F; Silva C; Mor M; Di Marzo V; Corelli F
J Med Chem; 2016 Feb; 59(3):1052-67. PubMed ID: 26756097
[TBL] [Abstract][Full Text] [Related]
34. New pyridazinone-4-carboxamides as new cannabinoid receptor type-2 inverse agonists: Synthesis, pharmacological data and molecular docking.
Ragusa G; Gómez-Cañas M; Morales P; Rodríguez-Cueto C; Pazos MR; Asproni B; Cichero E; Fossa P; Pinna GA; Jagerovic N; Fernández-Ruiz J; Murineddu G
Eur J Med Chem; 2017 Feb; 127():398-412. PubMed ID: 28088085
[TBL] [Abstract][Full Text] [Related]
35. Synthesis, pharmacological evaluation and docking studies of pyrrole structure-based CB2 receptor antagonists.
Ragusa G; Gómez-Cañas M; Morales P; Hurst DP; Deligia F; Pazos R; Pinna GA; Fernández-Ruiz J; Goya P; Reggio PH; Jagerovic N; García-Arencibia M; Murineddu G
Eur J Med Chem; 2015 Aug; 101():651-67. PubMed ID: 26209834
[TBL] [Abstract][Full Text] [Related]
36. Scaffold hopping strategy toward original pyrazolines as selective CB₂ receptor ligands.
Gembus V; Furman C; Millet R; Mansouri R; Chavatte P; Levacher V; Brière JF
Eur J Med Chem; 2012 Dec; 58():396-404. PubMed ID: 23151320
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and structure activity relationship investigation of triazolo[1,5-a]pyrimidines as CB2 cannabinoid receptor inverse agonists.
Aghazadeh Tabrizi M; Baraldi PG; Ruggiero E; Saponaro G; Baraldi S; Poli G; Tuccinardi T; Ravani A; Vincenzi F; Borea PA; Varani K
Eur J Med Chem; 2016 May; 113():11-27. PubMed ID: 26922225
[TBL] [Abstract][Full Text] [Related]
38. Tricyclic pyrazoles part 7. Discovery of potent and selective dihydrothienocyclopentapyrazole derived CB2 ligands.
Pinna G; Curzu MM; Dore A; Lazzari P; Ruiu S; Pau A; Murineddu G; Pinna GA
Eur J Med Chem; 2014 Oct; 85():747-57. PubMed ID: 25134064
[TBL] [Abstract][Full Text] [Related]
39. Discovery of 1a,2,5,5a-tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalen-4-carboxamides as potent and selective CB2 receptor agonists.
Han S; Thoresen L; Zhu X; Narayanan S; Jung JK; Strah-Pleynet S; Decaire M; Choi K; Xiong Y; Yue D; Semple G; Thatte J; Solomon M; Fu L; Whelan K; Al-Shamma H; Gatlin J; Chen R; Dang H; Pride C; Gaidarov I; Unett DJ; Behan DP; Sadeque A; Usmani KA; Chen C; Edwards J; Morgan M; Jones RM
Bioorg Med Chem Lett; 2015 Jan; 25(2):322-6. PubMed ID: 25488844
[TBL] [Abstract][Full Text] [Related]
40. Design and synthesis of novel tri-aryl CB2 selective cannabinoid ligands.
Bhattacharjee H; Gurley SN; Moore BM
Bioorg Med Chem Lett; 2009 Mar; 19(6):1691-3. PubMed ID: 19230659
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
